In addition to S100, the liquid biopsy approach is gaining interest in determining prognosis and predicting treatment, specifically in patients with malignant melanoma through the detection of BRAF mutations in circulating tumor DNA (ctDNA) or the evaluation of circulating tumor cells (CTC) [13, 14, 15]. This evidence concerns the gene S100A1 and neoplasm.